Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
Company Founded by MPM Capital, with Financing Co-Led by MPM Capital, EcoR1 Capital and Vida Ventures
Proprietary Technology Platform Harnesses the Power of Alpha Particles to Target Solid Tumors
Company Led by Industry Veteran Matthew Roden, PhD, Pr... Biopharmaceuticals, Oncology, Venture Capital, Personnel Aktis Oncology, radiopharmaceuticals, alpha radiotherapy, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news